Recent Analysts’ Ratings Updates for Boston Scientific (BSX)

A number of firms have modified their ratings and price targets on shares of Boston Scientific (NYSE: BSX) recently:

• 6/5/2026 – Boston Scientific was downgraded by Zacks Research from “hold” to “strong sell”.
• 6/4/2026 – Boston Scientific had its price target lowered by Truist Financial Corporation from $85.00 to $64.00. They now have a “buy” rating on the stock.
• 6/2/2026 – Boston Scientific had its price target lowered by BTIG Research from $80.00 to $65.00. They now have a “buy” rating on the stock.
• 6/1/2026 – Boston Scientific had its price target lowered by Canaccord Genuity Group Inc. from $71.00 to $70.00. They now have a “buy” rating on the stock.
• 5/29/2026 – Boston Scientific was downgraded by Wolfe Research from “outperform” to “peer perform”.
• 5/28/2026 – Boston Scientific had its “outperform” rating reaffirmed by Royal Bank Of Canada.
• 5/28/2026 – Boston Scientific was given a new $71.00 price target by The Goldman Sachs Group, Inc..
• 5/28/2026 – Boston Scientific had its price target lowered by Citigroup Inc. from $87.00 to $70.00. They now have a “buy” rating on the stock.
• 5/28/2026 – Boston Scientific was given a new $70.00 price target by Robert W. Baird.
• 5/28/2026 – Boston Scientific had its price target lowered by Leerink Partners from $87.00 to $74.00. They now have an “outperform” rating on the stock.
• 5/28/2026 – Boston Scientific had its price target lowered by Barclays PLC from $96.00 to $89.00. They now have an “overweight” rating on the stock.
• 5/28/2026 – Boston Scientific had its “equal weight” rating reaffirmed by Wells Fargo & Company. They now have a $55.00 price target on the stock, down from $75.00.
• 5/28/2026 – Boston Scientific was downgraded by Wells Fargo & Company from “overweight” to “equal weight”. They now have a $55.00 price target on the stock, down from $75.00.
• 5/27/2026 – Boston Scientific was given a new $75.00 price target by Stifel Nicolaus.
• 5/19/2026 – Boston Scientific had its price target lowered by Robert W. Baird from $78.00 to $75.00. They now have an “outperform” rating on the stock.
• 5/18/2026 – Boston Scientific had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $77.00 price target on the stock.
• 5/18/2026 – Boston Scientific had its price target lowered by Bank of America Corporation from $105.00 to $68.00. They now have a “buy” rating on the stock.
• 5/18/2026 – Boston Scientific had its “buy” rating reaffirmed by BTIG Research. They now have a $80.00 price target on the stock.
• 5/13/2026 – Boston Scientific was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.
• 4/29/2026 – Boston Scientific was downgraded by Daiwa Securities Group Inc. from “strong-buy” to “hold”.
• 4/23/2026 – Boston Scientific had its price target lowered by Royal Bank Of Canada from $105.00 to $100.00. They now have an “outperform” rating on the stock.
• 4/23/2026 – Boston Scientific was given a new $90.00 price target by Oppenheimer Holdings, Inc..
• 4/23/2026 – Boston Scientific had its price target lowered by Canaccord Genuity Group Inc. from $109.00 to $71.00. They now have a “buy” rating on the stock.
• 4/23/2026 – Boston Scientific had its price target lowered by Wells Fargo & Company from $94.00 to $75.00. They now have an “overweight” rating on the stock.
• 4/23/2026 – Boston Scientific had its price target lowered by Barclays PLC from $124.00 to $96.00. They now have an “overweight” rating on the stock.
• 4/23/2026 – Boston Scientific had its price target lowered by Needham & Company LLC from $97.00 to $77.00. They now have a “buy” rating on the stock.
• 4/23/2026 – Boston Scientific had its price target lowered by Robert W. Baird from $86.00 to $78.00. They now have an “outperform” rating on the stock.
• 4/23/2026 – Boston Scientific had its price target lowered by Truist Financial Corporation from $90.00 to $85.00. They now have a “buy” rating on the stock.
• 4/22/2026 – Boston Scientific had its price target lowered by The Goldman Sachs Group, Inc. from $87.00 to $84.00. They now have a “buy” rating on the stock.
• 4/22/2026 – Boston Scientific had its price target lowered by BTIG Research from $90.00 to $80.00. They now have a “buy” rating on the stock.
• 4/22/2026 – Boston Scientific had its price target lowered by Jefferies Financial Group Inc. from $110.00 to $100.00. They now have a “buy” rating on the stock.
• 4/22/2026 – Boston Scientific had its price target lowered by Barclays PLC from $124.00 to $100.00. They now have an “overweight” rating on the stock.
• 4/21/2026 – Boston Scientific had its price target lowered by Stifel Nicolaus from $90.00 to $85.00. They now have a “buy” rating on the stock.
• 4/15/2026 – Boston Scientific had its price target lowered by Truist Financial Corporation from $92.00 to $90.00. They now have a “buy” rating on the stock.
• 4/13/2026 – Boston Scientific had its price target lowered by Mizuho from $115.00 to $90.00. They now have an “outperform” rating on the stock.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig purchased 3,580 shares of the firm’s stock in a transaction on Wednesday, May 20th. The shares were purchased at an average cost of $56.68 per share, with a total value of $202,914.40. Following the purchase, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. This represents a 16.44% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Cheryl Pegus purchased 1,770 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was acquired at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the purchase, the director owned 1,770 shares in the company, valued at $99,987.30. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 9,800 shares of company stock valued at $554,012 over the last quarter. Insiders own 0.34% of the company’s stock.

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.